Rare diseases
Investigational molecules
Locations
55 Chapel Street Suite 200, 02458-1070, United States
Abcuro Inc. demonstrates a concentrated focus on developing innovative treatments for hematologic malignancies, with particular emphasis on addressing challenging forms of blood cancers. The company's research portfolio targets patients with relapsed or refractory disease, representing a critical unmet medical need where conventional therapies have proven insufficient.
The therapeutic strategy encompasses interventions for patients who have experienced disease progression following standard treatment regimens, including those with prior exposure to hypomethylating agents. This research direction addresses a patient population with limited therapeutic options and represents an area of significant clinical challenge in contemporary hematology.
Abcuro Inc. runs clinical trials in conditions such as Inclusion body myositis, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
BelgiumBelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
